On February 11, 2019 Nektar Therapeutics (Nasdaq: NKTR) reported that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time, during the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (GU), which will be held February 14-16, 2019 at Moscone West in San Francisco, CA (Press release, Nektar Therapeutics, FEB 11, 2019, https://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-with-urothelial-cancer-specialist-for-analysts–investors-at-the-2019-asco-genitourinary-cancers-symposium-300793500.html [SID1234533223]). The event will follow a presentation of preliminary efficacy, safety and immune monitoring data from the ongoing urothelial carcinoma patient cohort in the PIVOT-02 study evaluating bempegaldesleukin* (NKTR-214) in combination with nivolumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analyst Call with Urothelial Cancer Specialist:

Date and Time: Friday, February 15, 2019 at 2:00 p.m. Pacific Time
Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)
Passcode: 9688945

The conference call will include PIVOT-02 investigator Arlene O. Siefker-Radtke, M.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and Clinical Co-leader of the Bladder Cancer SPORE Executive Committee. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at View Source The web broadcast of the conference call will be available for replay through March 15, 2019.

Details on the Data Presentation at ASCO (Free ASCO Whitepaper)-GU:

Abstract Title: NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02
Abstract #: 388
Presenter: Arlene O. Siefker-Radtke, M.D., The University of Texas MD Anderson Cancer Center
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
Poster Board: G1
Date and Time: Friday, February 15, 2019, 12:15-1:45 p.m. and 5:15-6:15 p.m. Pacific Time